Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. Risk Factors and Presentation2. Staging and Paraneoplastic syndromes3. Localized Therapy Options and Considerations4. Evidence and Limitations for Adjuvant Systemic Therapy CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and

1. Immunohistochemistry of urothelial cancer2. History of systemic therapy in advanced and metastatic disease3. Pembrolizumab and Enfortumab Vedotin4. Approach to second line therapy and beyondCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published b

1. Etymology, presentation, and work-up of bladder/urothelial cancer2. Role of perioperative systemic therapy3. Tri-modality therapy (bladder sparing approach)4. Considerations for upper tract urothelial cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guid

1. Clinical presentation and work-up2. Intestinal and pancreatobiliary subtypes3. Role of perioperative therapy4. Considerations for metastatic diseaseCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local

1. On continuation of ADT and ARAT switch2. Systemic therapy options after progression3. Improper mandated crossover4. PARP inhibitors in prostate cancerCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations loc

1. The chemotherapy revolution in prostate cancer2. Role of ARATs in earlier disease states3. Triple therapy (chemotherapy, ADT, and ARAT)4. Considerations for frailer patients with indolent disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publi

1. Physiology, efficacy and toxicities of androgen deprivation2. Evidence for adjuvant intervention after definitive surgery or radiation3. Role of abiraterone in high-risk localized prostate cancer4. Limited evidence to support definitive salvage approachCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Upt

1. Background and presentation of prostate Cancer2. Evidence behind PSA screening and hallmarks of a screening test3. Staging and risk stratification of Localized Disease4. Management options and the ProtecT TrialCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of gu

We have updated our initial introduction and are re-posting it here as well as in the initial file.

1. Role for definitive chemotherapy and radiation2. Controversy on induction chemotherapy3. Considerations for nasopharyngeal cancer4. Approach to metastatic HNSCCCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organiz